Activist investor Glenview Capital is reducing its stake in healthcare giant CVS Health following its first-quarter earnings ...

Following healthy Q1 results and increased annual guidance, Glenview reduced its overall ... With this rebalancing, CVS Health remains our largest position, and we have no plans for additional ...

Trump's drug pricing order delivers blow to pharmacy benefit managers President Donald Trump on Monday delivered a blow to the private-sector middlemen who negotiate U.S. drug prices in his ...

Proxy advisor opposes Holcim chairman's $58 million compensation package Proxy advisor Ethos has called on Holcim shareholders to reject the company's remuneration proposals, saying Chairman Jan ...

Shareholders appeared unconcerned with CVS Health Corporation's (NYSE:CVS) lackluster earnings report last week. Our analysis suggests that while the profits are soft, the foundations of the ...

Big retailers’ ambitions to disrupt healthcare are falling apart. Companies have run into difficulties trying to make ...

CVS and Oak Street Health opened its first integrated clinic in South Carolina. The North Charleston center provides primary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.

The latest price target for CVS Health (NYSE:CVS) was reported by RBC Capital on May 5, 2025. The analyst firm set a price target for $81.00 expecting CVS to rise to within 12 months (a possible ...

Attorney General Andrea Campbell and a few of her peers sued CVS on Wednesday, alleging the pharmacy giant for years failed to provide Medicaid members with access to ...